This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MAPK6 / Mitogen-activated protein kinase 6 · IHC design guide
Design Immunohistochemistry for MAPK6
Plan chromogenic MAPK6 IHC in paraffin sections using high-staining glandular cells or kidney tubules as positive controls (HPA tissue IHC). The catalog antibody PB9666 has an IHC dilution of 0.5–1 µg/mL; assess cytoplasmic staining against a negative control (datasheet PB9666; HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MAPK6 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining; nuclear location also annotated (HPA tissue IHC; UniProt) | |
| Staining pattern | General cytoplasmic staining; high in glandular cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet PB9666) | |
| Positive control | Breast+4 more · see all | |
| Negative control | Oral mucosa |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image PB9666) | |
| Caveat | Staining varies by cell type; oral squamous cells were undetected (HPA tissue IHC) | |
| Regulation | Expression regulation unreported (UniProt) | |
| Isoform / epitope | No reported isoforms or cleavage; no extracellular domain (UniProt) |
Section 1
Recommended MAPK6 IHC & IF Protocols
The catalog antibody protocol uses EDTA pH 8.0 retrieval (datasheet PB9666). The published MAPK6 IHC protocol uses heated citrate pH 6.0 (PMC8589317).
| Sample | Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet PB9666) |
| Fixation | Image fixative and duration unreported (datasheet PB9666); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet PB9666); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet PB9666) |
| Primary antibody | Rabbit anti-MAPK6, 0.5-1μg/ml (datasheet PB9666) |
| Primary incubation | Overnight at 4 °C (datasheet PB9666) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9666) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MAPK6-positive staining in glandular cells of breast (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 HIER for the catalog antibody (datasheet PB9666); consider citrate pH 6.0 when adapting the published protocol (PMC8589317).
Section 2
What Is the Expected MAPK6 Staining Pattern?
Expect mainly cytoplasmic MAPK6 staining in paraffin sections, including breast and duodenal glandular cells, kidney tubule cells, and pancreatic exocrine cells (HPA: general cytoplasmic expression; High in those cells). Nuclear MAPK6 is also possible, and the protein has no transmembrane segment (UniProt Q16659: subcellular location and topology). Treat the tissue pattern as a guide: HPA rates its IHC reliability Approved, with medium staining–RNA consistency and external verification pending (HPA: tissue IHC).
| Clear cytoplasmic chromogen in glandular or tubule cells, with visible cell boundaries and little staining outside cells. | This fits the reported general cytoplasmic pattern and High staining in breast, duodenum, endometrium, prostate, pancreas, and kidney cell populations (HPA: tissue IHC). Compare the exact cell population on the section; a positive tissue does not imply that every cell in it should stain (HPA: cell-specific tissue IHC). |
| Signal appears mainly in lumens or extracellular material, without convincing intracellular staining. | Check for a staining artefact: MAPK6 is reported in cytoplasm and nucleus and has no transmembrane segment (UniProt Q16659: location and topology). Do not reject every membrane-adjacent signal automatically; Purkinje cells are described as cytoplasm/membrane High in cerebellum (HPA: tissue IHC). |
| Strong staining appears in oral mucosa squamous cells while the expected positive cell populations are weak. | Investigate antibody cross-reactivity or endogenous chromogen-generating activity with appropriate controls (general IHC practice). HPA reports MAPK6 as Not detected in oral mucosa squamous cells, but its Approved IHC profile has medium consistency with RNA and awaits external verification (HPA: tissue IHC). |
| A diffuse brown haze covers several cell types, including spaces where cellular MAPK6 cannot be assessed. | This obscures the expected cytoplasmic distribution (HPA: general cytoplasmic expression). Assess a no-primary control for endogenous detection activity and review blocking, washing, and antibody concentration as general chromogenic IHC checks (general IHC practice); the haze alone cannot establish MAPK6 localisation. |
| No interpretable signal appears in kidney tubules or pancreatic exocrine cells on a test section. | HPA reports High staining in those populations, so a blank result warrants a technical check (HPA: tissue IHC). Verify section integrity, retrieval, antibody application, and detection with suitable controls (general IHC practice). A single negative section cannot establish absence of MAPK6, especially given the stated HPA verification limit (HPA: reliability description). |
💡Expected MAPK6 appearanceA convincing positive is High, chiefly intracellular cytoplasmic staining in an HPA-listed glandular, tubule, or exocrine population (HPA: tissue IHC); dominant luminal deposits without cell staining warrant an artefact check (UniProt Q16659: location and topology; general IHC practice).
| Choice of positive and lower-signal tissue | Breast glandular cells, kidney tubule cells, and pancreatic exocrine cells offer reported High IHC patterns; oral mucosa squamous cells are reported Not detected, while smooth muscle cells and adipocytes are Low (HPA: tissue IHC). Use those observations as comparison patterns, allowing for the stated medium staining–RNA consistency (HPA: reliability description). |
| Compartment and topology | A predominantly cytoplasmic result matches the HPA tissue profile; UniProt also lists the nucleus and reports cytoplasmic translocation following interaction with MAPKAPK5 (HPA: tissue IHC; UniProt Q16659: subcellular location). With no transmembrane segment, isolated extracellular staining needs scrutiny (UniProt Q16659: topology; general IHC practice). |
| Antibody validation limits | The three listed antibodies each have Approved IHC status, while the tissue profile has medium staining–RNA consistency and awaits external verification (HPA: antibody validation and tissue reliability). Approved status supports using the reported pattern for comparison; resolve an unexpected result with controls rather than treating that status as proof of specificity in every section (general IHC practice). |
| IF/ICC localisation cross-check: what should fluorescence show? | Mainly cytosolic signal, with additional microtubule and primary-cilium localisation, is the HPA ICC-IF pattern (HPA: subcellular localisation). That observation can help interpret compartment differences, but it comes from ICC-IF and does not establish how frequently these structures will be visible in chromogenic paraffin sections (HPA: ICC-IF; general IHC practice). |
| Target-specific processing and fixation evidence | UniProt lists a single MAPK6 chain spanning residues 1–721, with no signal peptide or propeptide and zero glycosylation sites (UniProt Q16659: processing and glycosylation). The supplied UniProt and HPA records give no target-specific fixation-sensitivity result; do not infer a MAPK6 fixation effect from these features. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected positive cells are blank. | Retrieval, antibody application, or detection may have failed (general IHC practice); kidney tubule and pancreatic exocrine cells are reported High (HPA: tissue IHC). | Run a suitable positive control and check the recorded retrieval and detection steps, then reassess staining specifically in the expected cells (general IHC practice; HPA: tissue IHC). |
| Brown stain persists without primary antibody. | Endogenous detection activity can produce chromogen independently of primary-antibody binding (general chromogenic IHC practice). | Review the no-primary control, endogenous-activity blocking, and detection chemistry before assigning the signal to MAPK6 (general IHC practice). |
| Most structures show a uniform brown haze. | Excess nonspecific reagent binding or incomplete washing can obscure the reported cytoplasmic pattern (general IHC practice; HPA: tissue IHC). | Inspect blocking and wash steps, and reassess antibody concentration against positive and no-primary controls (general IHC practice). |
| Staining is dominated by extracellular or luminal deposits. | The distribution conflicts with reported intracellular localisation and no transmembrane segment (UniProt Q16659: location and topology). | Inspect the section and controls for precipitate or nonspecific deposition; score cellular staining separately (general IHC practice). |
| Nuclear staining accompanies cytoplasmic staining. | UniProt lists both nucleus and cytoplasm and notes cytoplasmic translocation after MAPKAPK5 interaction (UniProt Q16659: subcellular location). | Record nuclear and cytoplasmic staining separately and compare them with morphology and controls; do not classify nuclear signal as artefact solely by compartment (UniProt Q16659: subcellular location; general IHC practice). |
| Unexpected cells stain strongly while reference cells do not. | Cross-reactivity or background is possible (general IHC practice); HPA's Approved profile has medium staining–RNA consistency (HPA: tissue reliability). | Check cell identity and controls, then compare the result with HPA's named High and Not detected populations before interpreting the unexpected staining (HPA: tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing MAPK6 staining
PB9666 · IHCIHC analysis of MAPK6 using anti-MAPK6 antibody (PB9666). MAPK6 was detected in a paraffin-embedded section of human lung cancer tissue. Hea
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000069956-MAPK6/tissue/cerebral+cortex#imid_7565168
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000069956-MAPK6/tissue/colon#imid_7566678
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000069956-MAPK6/tissue/liver#imid_7566671
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000069956-MAPK6/tissue/kidney#imid_7566672
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA030262; green = MAPK6, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA030262; green = MAPK6, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MAPK6 IHC & IF
🧪Run kidney first: tubular cells should stain strongly (HPA: High in cells in tubules). Run oral mucosa as the negative tissue (HPA: Not detected in squamous epithelial cells); within the kidney section, nontubular cells that lack chromogenic signal can serve as internal background comparators, but their MAPK6 status must be verified rather than assumed.
Positive control tissue: Breast (Glandular cells, HPA High)
Negative control tissue: Oral mucosa (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MAPK6 in A-431, U-251MG, U2OS, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), NIH 3T3, with annotated localisation: Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; a rabbit IgG isotype control matched to the primary antibody’s clonality where applicable; and MAPK6-knockout material as a biological negative. For kidney sections, block endogenous peroxidase and check for endogenous biotin before using the caption’s streptavidin–biotin/DAB detection (caption: biotinylated secondary, SABC and DAB).
⚠️Feasibility: The selected PB9666 paraffin-section caption uses heat retrieval in EDTA at pH 8.0, but reports no fixative or target-specific fixation window (caption: retrieval conditions; fixative unreported). HPA ICC-IF images support a cellular localization readout, mainly in the cytosol (HPA: Cytosol approved); the supplied evidence does not establish whether IF or frozen sections are easier than paraffin IHC. Kidney endogenous biotin may add background with the caption’s SABC detection (caption: SABC; standard IHC practice).
HPA tissue IHC evidence for MAPK6
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells - cytoplasm/membrane | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Endometrium | Glandular cells | High | Protein (IHC) | HPA → |
| Kidney | Cells in tubules | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Oral mucosa | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced MAPK6 IHC Tips
Troubleshoot MAPK6 staining in paraffin sections by checking retrieval, controls, cellular location, and scoring before interpreting chromogenic signal.
How should I retrieve MAPK6 in paraffin sections when staining is weak?
Use heat-mediated EDTA retrieval at pH 8.0 for paraffin sections (datasheet PB9666). The product image used this retrieval before incubation with 1 μg/mL antibody overnight at 4°C (datasheet PB9666). If staining is weak, vary heating duration on adjacent sections while keeping the EDTA buffer and antibody concentration constant, then compare morphology and signal. Record the heating and cooling times because the image caption does not specify them (datasheet PB9666). Include a positive control tissue, such as kidney with tubular-cell staining (HPA: High in kidney tubular cells), in each retrieval comparison.
Can fixation explain inconsistent MAPK6 staining between paraffin blocks?
Target-specific sensitivity to fixation is unknown: the selected paraffin-section caption does not state a fixative or fixation duration (datasheet PB9666). Document the fixative, time before fixation, and fixation interval for each block before comparing signal across specimens. For newly prepared material, keep those variables consistent; 10% neutral buffered formalin is a conventional IHC fixative, but its effect on this antibody has not been established here. Process a control tissue alongside study blocks and apply the same EDTA pH 8.0 retrieval (datasheet PB9666). Treat differences between blocks as provisional until staining and tissue preservation are comparable.
Should MAPK6 staining be cytoplasmic, nuclear, or both?
Score cytoplasmic staining first because the tissue-IHC profile is generally cytoplasmic (HPA: tissue IHC profile). Nuclear signal can be biologically plausible because MAPK6 is annotated in both cytoplasm and nucleus (UniProt Q16659: subcellular location). MAPK6 can translocate toward the cytoplasm after interaction with MAPKAPK5 (UniProt Q16659: subcellular location). In a section stained with the catalog antibody at 1 μg/mL overnight at 4°C (datasheet PB9666), compare each compartment against a matched no-primary control. Record nuclear and cytoplasmic scores separately, and reject diffuse staining that also appears outside intact cells.
How can epitope uncertainty affect MAPK6 IHC interpretation?
The supplied record lists one 721-aa MAPK6 chain and 0 annotated isoforms (UniProt Q16659: processing and isoforms). Its kinase domain spans residues 20–316, and Ser-189 is a documented phosphorylation site (UniProt Q16659: domains and modified residues). The catalog antibody’s binding epitope is not supplied, so these annotations cannot establish whether phosphorylation or retrieval changes its binding. Keep EDTA at pH 8.0 during initial comparisons (datasheet PB9666). If an unexpected pattern persists, compare an independently validated antibody with a documented distinct epitope and use a loss-of-target control where available.
How should IF help resolve an ambiguous chromogenic MAPK6 pattern?
Use IF as a follow-up localisation check, while interpreting the paraffin-section IHC with its own controls. Multiplex MAPK6 with an epithelial marker in kidney tubules, where tubular cells show high tissue-IHC staining (HPA: High in kidney tubular cells). Choose a far-red fluorophore when tissue autofluorescence obscures shorter wavelengths, and collect single-label and no-primary controls to check bleed-through and background. MAPK6 has no transmembrane segment and is mainly cytosolic in subcellular imaging, so permeabilise cells for access to intracellular antigen (UniProt Q16659: topology; HPA: subcellular location). No IF conditions for PB9666 are supplied here; optimise permeabilisation and antibody concentration separately from its IHC protocol.
What causes diffuse brown background in MAPK6 chromogenic IHC?
Begin by comparing the section with a no-primary control and checking whether brown deposit tracks tissue edges, damaged areas, or endogenous pigment. The product image used 10% goat serum blocking, a biotinylated secondary, an avidin-biotin detection complex, and DAB (datasheet PB9666). For that workflow, include standard endogenous peroxidase blocking and assess endogenous biotin if background persists; these are general detection controls, not MAPK6-specific findings. Titrate primary antibody around the demonstrated 1 μg/mL concentration while keeping retrieval at EDTA pH 8.0 (datasheet PB9666). Judge improvement by signal in intact cells relative to the no-primary section.
How should I quantify MAPK6 staining across specimens? ⚠ ANSWER MARKED FOR VERIFICATION
Define viable tissue regions before scoring and exclude folds, edges, and necrotic areas using the counterstained section. For cytoplasmic MAPK6, record the percentage of positive cells and intensity from 0–3, then calculate an H-score from 0–300; tissue IHC reports a general cytoplasmic pattern (HPA: tissue IHC profile). If counting discrete positive cells, report density per mm² of viable tissue and identify the scored cell population. Normalise positive counts to all evaluable cells of that population, and keep thresholds, exposure, retrieval, and detection settings fixed across the comparison. Score nuclear staining separately because nuclear localisation is also annotated (UniProt Q16659: subcellular location).
How can I distinguish MAPK6 positivity from staining artefact?
Look for reproducible staining within intact cells and a pattern consistent with general cytoplasmic tissue staining (HPA: tissue IHC profile). Kidney tubular cells are a useful positive comparison, whereas oral-mucosal squamous epithelial cells were reported as not detected (HPA: High in kidney tubular cells; Not detected in oral mucosa squamous cells). Do not automatically discard nuclear staining because nuclear localisation is annotated (UniProt Q16659: subcellular location). Be cautious with signal confined to cut edges, necrotic regions, or a no-primary section; also check endogenous peroxidase when interpreting DAB. The HPA tissue-IHC rating has medium staining-to-RNA consistency and awaits external verification (HPA: reliability description), so corroborate unexpected patterns independently.
Boster reagents
Best MAPK6 / Mitogen-activated protein kinase 6 IHC Antibodies
PB9666 has a real IHC image from a human paraffin section (PB9666 image caption). A03011S189-1 lists IHC and IF applications, with human, mouse and rat reactivity; no IF image is supplied (catalog applications; catalog reactivity; catalog image alts).
Real IHC data
Anti-MAPK6 Antibody ®
Cat # PB9666
PB9666 has IHC data from a paraffin-embedded human lung cancer section and lists human, mouse and rat reactivity (PB9666 image caption; catalog reactivity). A03011S189-1 lists IHC and IF applications and human, mouse and rat reactivity, but supplies no IHC or IF image (catalog applications; catalog reactivity; catalog image alts).
Which to pick: Choose PB9666 for paraffin-section IHC because its own image documents chromogenic staining at 1 μg/ml; the fixative is unreported (PB9666 image caption). For IF, consider the polyclonal phospho-S189 antibody A03011S189-1 at its listed 1:50 dilution; ICC validation is unreported (A03011S189-1 dilution_raw; catalog applications). Both list human, mouse and rat reactivity for cross-species planning, while the supplied tissue image documents human staining only (catalog reactivity; PB9666 image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q16659 (MK06_HUMAN, Mitogen-activated protein kinase 6).
- Human Protein Atlas. MAPK6 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. MAPK6 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the microtubules and primary cilium..
- Human Protein Atlas. MAPK6 antibody validation summary (3 antibodies).
- Increased methylation of ZNF671 suppresses tumor progression by promoting MAPK6 transcription in laryngeal carcinoma. International journal of biological sciences 2023 — PMC10197888.
- Rab31 promotes the invasion and metastasis of cervical cancer cells by inhibiting MAPK6 degradation. International journal of biological sciences 2022 — PMC8692139.
- Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice. Molecular oncology 2022 — PMC8895443.
- MAPK6-AKT signaling promotes tumor growth and resistance to mTOR kinase blockade. Science advances 2021 — PMC8589317.
- PubMed PMID:7969157 — UniProt-cited evidence.
- PubMed PMID:8875998 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MAPK6 (Mitogen-activated protein kinase 6). Expected localisation Cytoplasmic tissue staining; nuclear location also annotated (HPA tissue IHC; UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet PB9666). Validated IHC antibody: PB9666 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Breast (Glandular cells); negative Oral mucosa. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet PB9666); 2. Fixation: Image fixative and duration unreported (datasheet PB9666); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet PB9666); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet PB9666); 8. Primary antibody: Rabbit anti-MAPK6, 0.5-1μg/ml (datasheet PB9666); 9. Primary incubation: Overnight at 4 °C (datasheet PB9666). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image PB9666); Caveat: Staining varies by cell type; oral squamous cells were undetected (HPA tissue IHC); Isoform / epitope: No reported isoforms or cleavage; no extracellular domain (UniProt); Regulation: Expression regulation unreported (UniProt). Evidence: UniProt Q16659, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the cytosol. In addition localized to the…, Datasheet PB9666, PMC8589317. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MAPK6/immunohistochemistry-ihc-guide.